. 2022 Jul 18;13:944041. doi: 10.3389/fphar.2022.944041

TABLE 5.

Pharmacokinetic parameters of the target analytes after the oral administration of cinobufacini capsule (0.9, 1.8, and 3.6 g/kg) and intravenous administration of cinobufacini injection at a dose of 9 ml/kg to male SD rats (mean ± SD, n = 6).

Analyte	Groups	C_max (μg/L)	T_max(h)	T_1/2z(h)	Vz/F (L/kg)	CLz/F (L/h/kg)	AUC_0-t (μg/L*h)	AUC_0-∞(μg/L*h)	MRT_0-t(h)	MRT_0-∞(h)
BF	Low	74.70 ± 30.70	0.25 ± 0.00	1.09 ± 0.91	1.81 ± 0.56	1.57 ± 0.69	139.28 ± 71.90	143.06 ± 79.36	2.04 ± 0.62	2.19 ± 0.90
	Medium	189.04 ± 43.18^A	0.43 ± 0.12^A	1.20 ± 0.62	2.15 ± 1.21	1.29 ± 0.43	310.28 ± 131.39^a	316.94 ± 133.54^a	1.45 ± 0.24^a	1.59 ± 0.49
	High	322.02 ± 55.54^AB	0.46 ± 0.17^a	1.27 ± 0.72	3.02 ± 2.01	1.64 ± 0.36	456.75 ± 91.19^Ab	460.64 ± 90.36^Ab	1.39 ± 0.43^a	1.49 ± 0.55
HBG	Low	2.47 ± 1.38	0.94 ± 0.75	1.02 ± 0.60	14.16 ± 3.88	14.2 ± 7.01	3.97 ± 1.73	4.21 ± 2.23	3.59 ± 1.63	3.81 ± 1.99
	Medium	8.36 ± 2.92^A	0.68 ± 0.35	1.34 ± 1.09	11.11 ± 5.04	6.63 ± 3.60	13.73 ± 4.30^A	13.84 ± 5.40^A	2.28 ± 1.26	2.55 ± 1.53
	High	18.16 ± 5.84^AB	0.39 ± 0.20	0.63 ± 0.10	6.35 ± 2.55^A	7.06 ± 2.71^a	31.07 ± 11.41^AB	31.07 ± 11.41^AB	2.14 ± 0.83	2.14 ± 0.82
DCT	Low	6.936 ± 5.35	0.87 ± 0.63	0.83 ± 0.25	5.16 ± 2.57	3.96 ± 1.01	12.98 ± 3.69	13.43 ± 3.76	2.53 ± 0.99	2.95 ± 1.78
	Medium	12.26 ± 3.11^A	0.61 ± 0.32	1.97 ± 1.36	8.27 ± 5.18	3.02 ± 0.78	34.24 ± 10.43^A	35.70 ± 12.05^A	2.68 ± 0.88	3.10 ± 0.92
	High	22.19 ± 5.19^AB	0.39 ± 0.20	1.53 ± 0.82	5.59 ± 3.29	2.55 ± 0.72^a	61.18 ± 16.14^AB	62.69 ± 16.75^AB	2.28 ± 0.37	2.53 ± 0.58
DCG	Low	17.20 ± 4.77	0.83 ± 0.20	1.22 ± 0.81	2.8 ± 1.71	0.78 ± 0.15	61.73 ± 7.80	66.97 ± 15.27	3.95 ± 0.73	4.74 ± 1.56
	Medium	35.61 ± 2.59^A	0.89 ± 0.13	4.76 ± 0.52^A	5.62 ± 0.68^a	0.72 ± 0.35	100.27 ± 12.45^A	112.49 ± 14.95^A	3.00 ± 0.63^a	4.86 ± 0.46
	High	56.62 ± 7.79^AB	0.82 ± 0.12	2.09 ± 0.60^B	2.79 ± 1.51^b	1.03 ± 0.22	147.67 ± 30.20^AB	150.43 ± 29.98^AB	2.44 ± 0.41^A	2.65 ± 0.44^AB
GBL	Low	13.28 ± 5.28	0.25 ± 0.00	0.37 ± 0.00	4.75 ± 0.98	9.00 ± 1.86	10.80 ± 2.45	13.59 ± 3.08	0.41 ± 0.11	0.64 ± 0.16
	Medium	21.48 ± 7.57^A	0.46 ± 0.23	0.28 ± 0.26	3.03 ± 2.02	12.57 ± 5.12	21.85 ± 11.62^A	23.38 ± 15.04^A	0.73 ± 0.10	0.79 ± 0.22
	High	49.50 ± 10.94^AB	0.36 ± 0.20	0.30 ± 0.16	3.74 ± 1.66	9.18 ± 2.66	54.00 ± 11.97^AB	54.52 ± 12.38^AB	0.83 ± 0.12	0.86 ± 0.14
ABG	Low	13.80 ± 6.40	0.45 ± 0.27	0.82 ± 0.66	8.01 ± 5.68	6.53 ± 2.41	15.50 ± 4.73	15.54 ± 4.73	1.44 ± 0.58	1.47 ± 0.60
	Medium	36.67 ± 13.05^A	0.32 ± 0.12	0.64 ± 0.16	4.20 ± 1.25	4.27 ± 1.06	44.08 ± 10.59^A	45.88 ± 13.11^A	1.49 ± 1.03	1.74 ± 1.29
	High	77.92 ± 24.22^AB	0.32 ± 0.12	0.89 ± 0.64	5.66 ± 3.45	4.65 ± 1.65	87.27 ± 27.35^AB	87.61 ± 27.83^AB	1.20 ± 0.26	1.23 ± 0.31
TCG	Low	35.25 ± 21.04	0.36 ± 0.20	0.16 ± 0.01	1.75 ± 0.60	7.71 ± 2.54	24.49 ± 10.27	24.49 ± 10.27	0.64 ± 0.06	0.64 ± 0.06
	Medium	109.08 ± 41.32^A	0.29 ± 0.09	0.21 ± 0.11	1.13 ± 0.37	3.97 ± 1.13^A	89.70 ± 23.80^A	89.93 ± 24.11^A	0.73 ± 0.11	0.74 ± 0.11
	High	253.40 ± 83.80^AB	0.32 ± 0.12	0.53 ± 0.02^AB	2.76 ± 1.67	3.62 ± 1.71^A	217.14 ± 82.40^AB	217.14 ± 82.40^AB	0.83 ± 0.13^A	0.83 ± 0.13^A
PBG	Low	9.30 ± 3.042	0.25 ± 0.00	1.52 ± 0.98	7.15 ± 2.16	2.01 ± 0.59	13.29 ± 4.42	13.80 ± 5.40	2.40 ± 0.63	2.76 ± 1.00
	Medium	24.50 ± 7.32^A	0.40 ± 0.22	1.03 ± 0.61	2.65 ± 1.51^a	1.85 ± 0.48	28.43 ± 6.26^A	28.55 ± 6.25^A	1.49 ± 0.08^a	1.54 ± 0.11^a
	High	42.84 ± 10.23^AB	0.32 ± 0.12	1.96 ± 0.67	5.65 ± 1.61^b	2.20 ± 0.48	47.26 ± 9.40^AB	47.70 ± 9.78^AB	1.47 ± 0.39^a	1.57 ± 0.39^a

^a p < 0.05, ^A p < 0.01, vs. low-dose group; ^b p < 0.05., ^B p < 0.01, vs. medium-dose group.